Drug Development

Generic drug developer receives U.S. FDA approval of sedative-reversing drug

Published in Medical Letter on the CDC and FDA, November 14th, 2004

Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration has granted final approval for the company's abbreviated new drug application (ANDA) for Flumazenil Injection, 0.1 mg/mL. Commercial marketing of this product will begin immediately.

Flumazenil Injection is the AP-rated generic equivalent for HLR Technology's Romazicon Injection, a product used to reverse the sedative effects of benzodiazepines.

The brand product has annual sales of approximately $48 million.

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 25 pharmaceutical companies and among the largest generic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-11-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry